Literature DB >> 35637334

Nanoformulations of flavonoids for diabetes and microvascular diabetic complications.

Kopal Agarawal1, Yogesh Anant Kulkarni1, Sarika Wairkar2.   

Abstract

Diabetes is a chronic metabolic disease characterized by an excess of glucose in the blood. If the constant sugar level is not managed correctly in diabetic patients, it may lead to microvascular complications such as diabetic retinopathy, neuropathy, and nephropathy. There are several synthetic drugs for the management of diabetes; however, these drugs produce immense adverse effects in long-term use. Flavonoids are naturally occurring substances categorized in various classes. They are known for their diverse pharmacological actions, and one of them is prominent antihyperglycemic action and their activities in diabetic complications. In the last few decades, many research studies emphasized the potential of flavonoids in diabetes management. Nevertheless, most flavonoids are insoluble in water and cannot produce desired therapeutic action when administered in conventional dosage forms. To overcome this issue, flavonoids were formulated into different nanoformulations to enhance solubility, absorption, and therapeutic efficacy. This review article focuses on flavonoid nanoformulations and in vitro and in vivo studies reported to overcome diabetes mellitus and its complications.
© 2022. Controlled Release Society.

Entities:  

Keywords:  Diabetes; Diabetic nephropathy; Diabetic neuropathy; Diabetic retinopathy; Flavonoid nanoformulations

Year:  2022        PMID: 35637334     DOI: 10.1007/s13346-022-01174-x

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  52 in total

1.  Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis : A Multicenter Cohort Study.

Authors:  Antonios Douros; Lisa M Lix; Michael Fralick; Sophie Dell'Aniello; Baiju R Shah; Paul E Ronksley; Éric Tremblay; Nianping Hu; Silvia Alessi-Severini; Anat Fisher; Shawn C Bugden; Pierre Ernst; Kristian B Filion
Journal:  Ann Intern Med       Date:  2020-07-28       Impact factor: 25.391

2.  Bevacizumab-induced serious side-effects: a review of the French pharmacovigilance database.

Authors:  Solène Taugourdeau-Raymond; F Rouby; A Default; M-J Jean-Pastor
Journal:  Eur J Clin Pharmacol       Date:  2012-02-16       Impact factor: 2.953

3.  Study of clinical applications and safety for Pascal® laser photocoagulation in retinal vascular disorders.

Authors:  Mahiul M K Muqit; Chintan Sanghvi; Rita McLauchlan; Christine Delgado; Lorna B Young; Stephen J Charles; George R Marcellino; Paulo E Stanga
Journal:  Acta Ophthalmol       Date:  2010-02-16       Impact factor: 3.761

Review 4.  Current Therapies for the Medical Management of Diabetes.

Authors:  Silvio E Inzucchi; Sachin K Majumdar
Journal:  Obstet Gynecol       Date:  2016-04       Impact factor: 7.661

Review 5.  Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.

Authors:  Andrea D Fass; Jennifer A Gershman
Journal:  Adv Ther       Date:  2013-04       Impact factor: 3.845

6.  Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study.

Authors:  M A Nauck; G C Ellis; P R Fleck; C A Wilson; Q Mekki
Journal:  Int J Clin Pract       Date:  2009-01       Impact factor: 2.503

Review 7.  Oral direct renin inhibition: premise, promise, and potential limitations of a new antihypertensive drug.

Authors:  Moiz M Shafiq; Dileep V Menon; Ronald G Victor
Journal:  Am J Med       Date:  2008-04       Impact factor: 4.965

Review 8.  Diabetic nephropathy - complications and treatment.

Authors:  Andy Kh Lim
Journal:  Int J Nephrol Renovasc Dis       Date:  2014-10-15

Review 9.  High-Sensitivity Cardiac Troponin Concentration and Risk of First-Ever Cardiovascular Outcomes in 154,052 Participants.

Authors:  Peter Willeit; Paul Welsh; Jonathan D W Evans; Lena Tschiderer; Charles Boachie; J Wouter Jukema; Ian Ford; Stella Trompet; David J Stott; Patricia M Kearney; Simon P Mooijaart; Stefan Kiechl; Emanuele Di Angelantonio; Naveed Sattar
Journal:  J Am Coll Cardiol       Date:  2017-08-01       Impact factor: 24.094

10.  Transfoveal Micropulse Laser Treatment of Central Serous Chorioretinopathy within Six Months of Disease Onset.

Authors:  Maciej Gawęcki; Agnieszka Jaszczuk-Maciejewska; Anna Jurska-Jaśko; Małgorzata Kneba; Andrzej Grzybowski
Journal:  J Clin Med       Date:  2019-09-06       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.